VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Safety management of CAR-T cell therapy in DLBCL

Ulrich Jäger, MD, of Medical University of Vienna, Vienna, Austria, discusses the short and long-term safety of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL) and the guidelines used to prevent CRS and neurotoxicities. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter